Allergy Therapeutics Share Price (AGY)
| Bid price | 13.75 | Open price | 13.77 |
|---|---|---|---|
| Ask price | 14.00 | Prev close | 13.88 |
| High price | 0.00 | Spread | 1.79% |
| Low price | 0.00 | Volume | 0 |
Register now for FREE live Allergy Therapeutics share prices, Allergy Therapeutics stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Allergy Therapeutics Level 2 Data, indepth research tools and investor commentary for Allergy Therapeutics (AGY) and other London Stock Exchange equities.
Allergy Therapeutics Share Price Chart
Register now for FREE Allergy Therapeutics share price charts
Allergy Therapeutics Share Price Information
| Name | Allergy Therapeutics | Epic | AGY |
|---|---|---|---|
| Sector | n/a | ISIN | GB00B02LCQ05 |
| Activites | n/a | Index | n/a |
Allergy Therapeutics Director Deals
| Dec.Date | Type | Director | Pos | No. of Shares |
|---|---|---|---|---|
| 22/01/2025 | BUY | Shaun Furlong | FD | 7 |
| 13/12/2023 | TIN | Manuel Llobet | RES | 1,676,200 |
| 11/11/2021 | BUY | Peter Jensen | RES | 30,000 |
| 20/11/2020 | BUY | Peter Jensen | RES | 100,000 |
| 15/10/2020 | EXR | Manuel Llobet | RES | 2,577,923 |
Allergy Therapeutics Company News
Director Deals - Allergy Therapeutics PLC (AGY)
Peter Jensen, Director, bought 100,000 shares in the company on the 19th November 2020 at a price of £0.14. The Director now holds 270,000 shares. Story provided by StockMarketWire.com Director deals data provided by www.sharesmagazine.co.uk
Grant of Awards under Long Term Incentive Plan
RNS Number : 0593G Allergy Therapeutics PLC 20 November 2020 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Grant of...
Director/PDMR Shareholding
RNS Number : 9406F Allergy Therapeutics PLC 20 November 2020 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Company") Director...
More Allergy Therapeutics Company News >>
Register now for FREE Allergy Therapeutics company news
Allergy Therapeutics Share Price Discussions
Allergy Therapeutics PLC (AGY)
Mission Statement To create a sustainable, fast-growing and profitable global speciality pharmaceutical business with a substantial franchise in the allergy sector by developing innovative, patented, registered therapies for both the treatment and prevention of allergy-related conditions....
Allergy TV Clip re: Successful Phase II Study (AGY)
Allergy Therapeutics (AGY)
Good morning, Below is a short TV interview with Manuel & Ian covering today's interim results. www.fmp-tv.co.uk/company/allergy-therapeutics-investors-video-and-news/
Register now for FREE Allergy Therapeutics share price discussions